Quarterly report · Q2
4596.TEDINET S100RMM5
Period2023-01-01 → 2023-06-30
Filed2023-08-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 59
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥17m | 2023-01-01 → 2023-06-30 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥12m | 2023-04-01 → 2023-06-30d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥8m | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Operating income | −¥747m | 2023-01-01 → 2023-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | −¥302m | 2023-04-01 → 2023-06-30d | Cons. | Operating profit loss IFRS |
| Operating income | −¥1.2bn | 2022-01-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | −¥528m | 2022-04-01 → 2022-06-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥745m | 2023-01-01 → 2023-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥300m | 2023-04-01 → 2023-06-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥2.0bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥1.2bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥541m | 2022-04-01 → 2022-06-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥745m | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥300m | 2023-04-01 → 2023-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥2.0bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥1.2bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥541m | 2022-04-01 → 2022-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥745m | 2023-01-01 → 2023-06-30 | Cons. | Profit loss IFRS |
| Net income | −¥300m | 2023-04-01 → 2023-06-30d | Cons. | Profit loss IFRS |
| Net income | −¥1.2bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | −¥541m | 2022-04-01 → 2022-06-30d | Cons. | Profit loss IFRS |
| Total assets | ¥3.8bn | at 2023-06-30 | Cons. | Assets IFRS |
| Total assets | ¥4.4bn | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥4.6bn | at 2022-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥412m | at 2023-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥470m | at 2022-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥3.4bn | at 2023-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥3.9bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥3.9bn | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥4.2bn | at 2021-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥3.4bn | at 2023-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥3.9bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥3.9bn | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥3.4bn | at 2023-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥4.0bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥3.9bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥4.0bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥738m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥2.1bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥1.2bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥6m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥505m | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥212m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥86m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥1.4bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥564m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-13.48 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-5.41 | 2023-04-01 → 2023-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-40.92 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-26.02 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-11.73 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-13.48 | 2023-01-01 → 2023-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-5.41 | 2023-04-01 → 2023-06-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-40.92 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-26.02 | 2022-01-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-11.73 | 2022-04-01 → 2022-06-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 89.1% | at 2023-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 89.4% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 85.3% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 465
| Item | Context | Value | Unit |
|---|---|---|---|
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | 24228000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1YTDDuration | -125912000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYTDDuration | -634767000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 3977312000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 4048969000 | JPY |
| Cash and cash equivalents IFRS | Prior1QuarterInstant | 3851400000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 3414202000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-08-10 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第９期第２四半期（自 2023年４月１日 至 2023年６月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)窪田製薬ホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | Kubota Pharmaceutical Holdings Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役会長、社長兼最高経営責任者 窪田 良 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区南青山一丁目15番37号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-6550-8928 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役、最高事業責任者 市川 今代 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区南青山一丁目15番37号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-6550-8928 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役、最高事業責任者 市川 今代 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E32854 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45960 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)窪田製薬ホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | Kubota Pharmaceutical Holdings Co., Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2023-01-01 | |
| Current period end date | FilingDateInstant | 2023-06-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2023-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2022-01-01 | |
| Comparative period end date | FilingDateInstant | 2022-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2022-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |